You're funny. You're either a soft basher (with a short position that you're trying to unwind) or the board now has an Eeyore.
We're getting close. I would say there's no volume for 6 on the Wednesday afternoon before T'giving -- but here we are up 4 percent on volume of less than 500K shares. So maybe.
Finally -- though it looked as though someone to have tried to put up a bit of a fight at 5.30 as well.
Deletion is his modus operandi. It enables him to post the same junk over and over again, and make it look like a new message every time.
Could be sectoral, actually. IBB and XBI also ticking up.
We're less liquid so a little buying pressure goes a long way.
I'm guessing it's a short who wants to unwind before the last hour of the second-to-last day before the next scripts report.
You ask whether that makes sense. I have no idea, but then again I've never shorted this name.
Honestly, though, I think Thursday is becoming a clear-the-decks-for-the-scripts-report day. And if that's right, then a short might want to unwind before the rush to the close on a Wednesday.
It's not a great theory but it's the best I can do.
Alternatively, perhaps someone at Stifel liked what they heard?
The question of the moment is whether all the nephrologists who were at Kidney Week went home more informed and enthusiastic about Auryxia than they were before.
Kidney Week was November 3 through 8.
So this Friday's scripts numbers will be the first, post-Kidney Week. Will they show a CME boost??
Props to user_6060 for noticing this.
Abrams Capital Management L.P. filed a Form 13-F showing that they hold 5,000,000 shares of Keryx.
As of the end of the quarter, this accounted for $17 million, which was barely 1 percent of the assets listed. They have about $1.2 billion under management. Of course it's now over $25 million.
Note that this is a new position. This entity's 13-F for the 2d quarter does not list Keryx.
"Anemia affects ~33% of the world population and accounts for 8.8% of global disability. Although the etiology of anemia is multifactorial, iron deficiency (ID) is considered to be the most prevalent cause globally. In the United States, ID is estimated to affect 9.2% of females aged 12 to 49 years."
October 22, 2015; Blood: 126 (17)
"Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women"
This has some interesting statistics on the prevalence of IDA, and on the difficulties in using oral therapies that are not Auryxia.